Jiangsu Hengrui Medicine wins multiple drug trial approvals

Jiangsu Hengrui Medicine Co. and its subsidiaries, Suzhou MediLink Therapeutics and Shanghai Hengrui Pharmaceuticals, announced the receipt of clinical trial approvals from the National Medical Products Administration for eight drug candidates. These include HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, adebrelimab injection, bevacizumab injection, SHR-A2102 for injection, famitinib malate capsules, and dalpiciclib tablets. The approvals pave the way for upcoming clinical trials, focusing on various oncology treatments.

The company has made substantial R&D investments in these candidates. HRS-4642 injection has seen cumulative R&D investment of approximately CNY 190.65m. SHR-1701 injection has accumulated approximately CNY 685.70m in R&D, while SHR-7367 injection has a cumulative R&D investment of approximately CNY 43.10m. SHR-8068 injection’s R&D investment totals around CNY 262.18m.

Additionally, adebrelimab injection, which was approved in February 2023, has a cumulative R&D investment of approximately CNY 968.98m. Bevacizumab injection, approved in June 2021, has received approximately CNY 364.73m in R&D. SHR-A2102 for injection has an R&D investment of approximately CNY 248.22m, famitinib malate capsules (approved May 2025) around CNY 258.65m, and dalpiciclib tablets (approved 2021) approximately CNY 1,287.02m.